PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17981262-4 2008 We show that 5-ASA down-regulates both constitutive and TNF-alpha or IL-1beta-induced COX-2 in HT-115 and HT-29 cells. Mesalamine 13-18 tumor necrosis factor Homo sapiens 56-65 10513809-10 1999 Tumor necrosis factor alpha-stimulated HMVEC shedding of sICAM-1 was reduced by incubation with either SSZ (19%) or 5-ASA (23%) (P<0.05; [n = 6]). Mesalamine 116-121 tumor necrosis factor Homo sapiens 0-27 16306769-8 2005 Moreover, tumor necrosis factor-alpha- or interleukin-1beta-induced CCL20 secretion was greatly diminished by 5-aminosalicylic acid and/or glucocorticoid treatment of human intestinal epithelial HT-29 cells. Mesalamine 110-131 tumor necrosis factor Homo sapiens 10-37 16407467-11 2006 Furthermore, combined TauCl/5-ASA treatment additively inhibited TNF-dependent NF-kappaB activation. Mesalamine 28-33 tumor necrosis factor Homo sapiens 65-68 16407467-12 2006 Together, our data suggest that the colon-specific carrier taurine contributes to the clinical effect of the prodrug by potentiating the inhibitory effect of the active ingredient 5-ASA on a major proinflammatory signal, TNF-dependent NF-kappaB activation in the inflamed large intestine. Mesalamine 180-185 tumor necrosis factor Homo sapiens 221-224 34259316-8 2021 Compared with those in the DSS group, the expressions of IL-1beta, IL-6, IL-17, and TNF-alpha in the DSS+DHA and DSS+5-aminosalicylic acid (5-ASA) groups were decreased, while the expressions of IL-4 and IL-10 were significantly upregulated. Mesalamine 117-138 tumor necrosis factor Homo sapiens 84-93 7496871-8 1995 5-Aminosalicylic acid did not modulate IL-6 synthesis, but significantly reduced IL-1 and enhanced TNF synthesis. Mesalamine 0-21 tumor necrosis factor Homo sapiens 99-102 1499439-9 1992 Furthermore, 5-aminosalicylic acid partially protected Cl.16E cells against cellular injury caused by IFN-gamma and TNF-alpha. Mesalamine 13-34 tumor necrosis factor Homo sapiens 116-125 32676662-10 2021 Patients on anti-tumor necrosis factor (anti-TNF) medications had the lowest probability of hospitalizations (overall 5-year probability in patients with IBD stratified by maximal therapeutic step: 5-aminosalicylic acids 37% [SD = 0.6%]; anti-TNFs 31% [SD = 1.8%]; P < 0.0001). Mesalamine 198-220 tumor necrosis factor Homo sapiens 17-38 32676662-10 2021 Patients on anti-tumor necrosis factor (anti-TNF) medications had the lowest probability of hospitalizations (overall 5-year probability in patients with IBD stratified by maximal therapeutic step: 5-aminosalicylic acids 37% [SD = 0.6%]; anti-TNFs 31% [SD = 1.8%]; P < 0.0001). Mesalamine 198-220 tumor necrosis factor Homo sapiens 45-48 26896068-9 2016 Moreover, metformin enhanced the anti-inflammatory effect of 5-ASA by decreasing the gene expression of IL-1beta, IL-6, COX-2 and TNF-alpha and its receptors; TNF-R1 and TNF-R2. Mesalamine 61-66 tumor necrosis factor Homo sapiens 130-139 30420398-1 2019 OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. Mesalamine 37-54 tumor necrosis factor Homo sapiens 157-160 30420398-1 2019 OBJECTIVE: The benefit of continuing 5-aminosalicylate (5-ASA) in patients with ulcerative colitis (UC) who initiate anti-tumour necrosis factor-alpha (anti-TNF) biologics is unknown. Mesalamine 56-61 tumor necrosis factor Homo sapiens 157-160 30420398-6 2019 Patients were classified as stopping 5-ASA if therapy was discontinued within 90 days of starting anti-TNF. Mesalamine 37-42 tumor necrosis factor Homo sapiens 103-106 30420398-12 2019 CONCLUSION: In two national databases, stopping 5-ASA in patients with UC starting anti-TNF therapy did not increase the risk of adverse clinical events. Mesalamine 48-53 tumor necrosis factor Homo sapiens 88-91 30329067-8 2019 Concomitant use of 5-aminosalicylate was associated with higher persistence of first-line anti-TNF treatment in the overall population (hazard ratio [HR] 0.5; 95% CI, 0.3-0.8; P = 0.002). Mesalamine 19-36 tumor necrosis factor Homo sapiens 95-98 30329067-13 2019 Concomitant use of 5-aminosalicylates was associated with higher persistence of first-line anti-TNF treatment. Mesalamine 19-37 tumor necrosis factor Homo sapiens 96-99 30630805-1 2018 Present investigation is conducted to investigate the clinical efficacy of mesalazine in combination with the Bifid Triple Viable Capsules on the ulcerative colitis (UC) and the resultant effect on the inflammatory factors (TNF-alpha, IL-8 and IL-10) of UC patients. Mesalamine 75-85 tumor necrosis factor Homo sapiens 224-233 32047894-5 2020 Overall infectious complications were increased in patients who received anti-tumor necrosis factor (TNF) agents (odds ratio [OR] 1.26; 95% confidence interval [CI], 1.07-1.50) and corticosteroids (OR 1.34; 95% CI, 1.25-1.44) and decreased in those who received 5-aminosalicylic acid (OR 0.63; 95% CI, 0.46-0.87). Mesalamine 262-283 tumor necrosis factor Homo sapiens 73-99 32047894-5 2020 Overall infectious complications were increased in patients who received anti-tumor necrosis factor (TNF) agents (odds ratio [OR] 1.26; 95% confidence interval [CI], 1.07-1.50) and corticosteroids (OR 1.34; 95% CI, 1.25-1.44) and decreased in those who received 5-aminosalicylic acid (OR 0.63; 95% CI, 0.46-0.87). Mesalamine 262-283 tumor necrosis factor Homo sapiens 101-104 32047894-7 2020 Both corticosteroids and anti-TNF agents were associated with increased intra-abdominal infection risk (OR 1.63; 95% CI, 1.33-2.00 and OR 1.46; 95% CI, 1.08-1.97, respectively), whereas no impact was observed with 5-aminosalicylates, immunomodulators, or anti-integrin therapy. Mesalamine 214-232 tumor necrosis factor Homo sapiens 30-33 29080069-9 2018 5-ASA treatment decreased ex vivo Be-stimulated BAL cell TNF-alpha levels within the 5-ASA group and when compared to placebo. Mesalamine 0-5 tumor necrosis factor Homo sapiens 57-66 29080069-11 2018 CONCLUSIONS: 5-ASA"s ability to decrease BAL cell BeLPT and Be-stimulated BAL cell TNF-alpha levels suggests that 5-ASA may impact the beryllium-specific immune response in CBD. Mesalamine 13-18 tumor necrosis factor Homo sapiens 83-92 29080069-11 2018 CONCLUSIONS: 5-ASA"s ability to decrease BAL cell BeLPT and Be-stimulated BAL cell TNF-alpha levels suggests that 5-ASA may impact the beryllium-specific immune response in CBD. Mesalamine 114-119 tumor necrosis factor Homo sapiens 83-92 25488057-9 2015 CONCLUSION: Anti-TNF agents may be more effective in preventing clinical and endoscopic postoperative Crohn"s disease recurrence than control treatment (thiopurines or mesalamine). Mesalamine 168-178 tumor necrosis factor Homo sapiens 17-20 25574095-9 2015 In multivariate analyses adjusting for gender, IBD type and duration of disease, these associations with mesalamine and anti-TNF remained significant [(adjusted values for mesalamine (OR = 0.43, 95%CI: 0.19-0.86) and anti-TNFs (OR = 0.28, 95%CI: 0.08-0.98)]. Mesalamine 172-182 tumor necrosis factor Homo sapiens 125-128 25320942-6 2014 Interstitial lung disease is a rare side effect of mesalazine probably underdiagnosed by physicians especially in patients treated with TNF alpha inhibitors. Mesalamine 51-61 tumor necrosis factor Homo sapiens 136-145 20926883-15 2010 Clinical practice should change such that combination therapy with an anti-TNF agent and azathioprine replace azathioprine in patients failing first line therapy with mesalamine and/or steroids. Mesalamine 167-177 tumor necrosis factor Homo sapiens 75-78 24056767-11 2014 CONCLUSIONS: Parallel to an increasing use of thiopurines and TNF-alpha blockers in IBD over time, a persistent significant decrease in surgery rates was observed along with a significant decrease in use of 5-ASA and corticosteroids. Mesalamine 207-212 tumor necrosis factor Homo sapiens 62-71 24379584-10 2013 Consistent with this observation, mesalazine and azathioprine induced, in primary fibroblasts, IL10RB and TNFRII over-expression and TNFRI and TNFalpha under-expression. Mesalamine 34-44 tumor necrosis factor Homo sapiens 143-151 19901345-7 2010 Be-stimulated CBD BAL cell IFN-gamma and TNF-alpha cytokine production was decreased by treatment with sulfasalazine or mesalamine. Mesalamine 120-130 tumor necrosis factor Homo sapiens 41-50 24982311-9 2014 CONCLUSIONS: Combination therapy with TNF-alpha inhibitors appears to be associated with a lower risk of pancreatitis in IBD patients on mesalamine, thiopurines, or a combination of both. Mesalamine 137-147 tumor necrosis factor Homo sapiens 38-47